Almost one decade ago, the first anti-VEGF drugs to treat neovascular eye disorders were approved by the respective health authorities and brought into routine clinical care. This “revolution” in the field of ophthalmology offered the treating physicians the chance to sustainably save vision for patients affected for the first time. Since these days, the understanding of the efficacy and safety profiles of the anti-VEGF drugs available has constantly grown. However, many open questions remain. Furthermore, new alternative and/or additional substances targeting VEGF and other factors such as PDGF and PIGF are on the horizon to alter and further improve our treatment strategies for neovascular eye diseases.

We invite investigators to contribute manuscripts of original research, clinical studies, and review articles on each aspect of anti-VEGF therapy for neovascular eye diseases. We are particularly interested in articles about new drugs in development or on their way into routine clinical care.

Potential topics include but are not limited to the following:

• Basic research related to anti-VEGF and new drugs for the treatment of neovascular eye diseases
• Clinical trials related to anti-VEGF and new drugs for the treatment of neovascular eye diseases
• Real-world evidence for the treatment of patients affected
• All aspects of individualized therapy
• Combining substances with different modes of action
• Whom, when, and how to switch different anti-VEGF drugs
• Treatment of retinal ischemia and/or neovascularization with anti-VEGF
• Treatment of corneal and anterior segment neovascularization